Aqualung Therapeutics, Corp
aqualungtherapeutics.com
Actively hiring
Higher Education
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
1
Florida Opportunity Fund
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 22, 2025
Certified Aqualung Therapeutics Receives FDA Clearance for Phase 2a Lung Fibrosis Study · marketwatch.com
Sep 22, 2021
Took on debt financing $3.1M · SEC Form D
2021
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Debt Financing | Sep 2021 | $3.1M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Aqualung Therapeutics Corp. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Stan MieleExecutive Officer, DirectorSEC Form D
Joe GarciaExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Florida Opportunity Fund Similar startupsby what they do, their industry and backers
Restoring Blood Flow, Renewing Life. Creating new vascular pathways through targeted cell therapy and biomaterial engineering.
Therapeutic Ultrasound-Based Solution for Vascular Care. cardiovascular disease is VTE. ¹.
Our advanced endoscopy product is a novel rigidizing overtube designed to manage loop formation & control your endoscope tip for diagnostic…
Restoring Self Tolerance to the Immune System to Transform the Treatment of Autoimmune Diseases.
L-Nutra — The Longevity Leader. Breakthrough nutrition technology aimed at optimizing healthspan, curing disease and extending life…
Maqsad provides mobile-first academic learning content for Pakistani students. Its app covers mathematics and science with local curriculum…
News
Fight Against COVID-19 May Yield Solutions to ARDS PharmExec
Combating ARDS, the biggest threat to COVID-19 patients, may lead to new treatments for the condition, writes physician and biotech CEO Joe G. N.
Read more
Report
Joe G.N. Garcia, Founder & CEO, Aqualung Therapeutics - caa
Joe G.N. Garcia, founder and CEO of Aqualung Therapeutics, spoke with Invest: about the development of a monoclonal antibody designed to reduce inflammation.
Read more
Report
Aqualung Therapeutics Receives FDA Clearance for Phase 2a Lung Fibrosis Study
Aqualung Therapeutics, a clinical-stage immunotherapeutics company, announced today that the Food and Drug Administration (FDA) has cleared its Phase 2a study of ALT-100 mAb as an anti-inflammatory and anti-fibrotic therapy in human subjects with Progress
Read more
Report
Aqualung Therapeutics Concludes ALT-100 Antibody (mAb) Dosing in Its P1a Study with no Reported SAE
Aqualung has selected Novotech as their CRO partner to conduct the P2a PUERTA study in moderate/severe ARDS subjects.Expected screening for enrolled subjects to begin April/May 2023.Aqualung Submitting an end of P1 (EOP1) meeting data packet to the FDA in
Read more
Report
NIH awards support Aqualung Therapeutics
Aqualung Therapeutics Corp. has been awarded two 3-year National Institutes of Health (NIH) Fast Track awards to support development of ALT-100 (enamptcumab), a humanized monoclonal antibody therapy for the chronic indications of pulmonary arterial hypert
Read more
Report
Read Press Release
CEO & Founder of Aqualung Therapeutics Corp., Joe G.N. Garcia MD to Present Corporate Update at the Annual Biotech Showcase - December 2021 Read Press Release
Read more
Report
Aqualung Therapeutics: eNAMPT, the Inflammation-Regulatory Protein Specifically Targeted by Aqualung Therapeutic's Monoclonal Antibody ALT-100, is now Tightly Linked to Outcomes in COVID-19 Infected Patients
TUCSON, AZ / ACCESSWIRE / February 11, 2021 / Several recent publications have now highlighted the involvement of extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in the pathobiology of SARS-CoV-2
Read more
Report
Report
Show more news
People
Stan Miele
Executive Officer, Director
Joe Garcia
Executive Officer, Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
1
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Tucson
United States
HQ
Aqualung Therapeutics Corporation
6080 N Pinchot Rd, Tucson, Az 85750
Jupiter
United States
Engineering / R&D
LABORATORY
130 Scripps Way, Jupiter, FL, 33458
Financials
Total raised
$3.1M
Latest round
Debt Financing
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Debt Financing | 2021 | $3.1M | Details |